Surgeries & Interventions

Ancora Heart’s AccuCinch TLVR HF Improvements

Ancora Heart Accucinch

New data presented at THT 2023 and published in JCF suggests that Ancora Heart’s investigational AccuCinch Transcatheter Left Ventricular Restoration (TLVR) system improves heart failure patients’ cardiac structure, quality of life, and function.

Ancora Heart’s AccuCinch TLVR is the first completely percutaneous device that reduces the size of the left ventricle, addressing a fundamental issue in systolic heart failure progression. The AccuCinch would be used in patients with severe HF that can no longer be managed by medications and pacemakers, and would otherwise require LVADs or heart transplants.

Twelve month analysis of the study’s 51 HFrEF subjects (LVEF 20-40%, MR ≤2+, 86% male, 56.3yrs avg) who were treated with optimal medical therapy and subsequently underwent AccuCinch TLVR, revealed significant improvements to:

  • End-diastolic volume (-33.6 ml), the primary outcome
  • LV free wall radius (-29.6% to 9.2 mm)
  • Quality of life scores (KCCQ-OS 16.4 pts)
  • Six-minute walk test distances (45.9 m)
  • NYHA classifications (65% improved ≥ 1, 94% improved or unchanged)
  • Ejection fraction (3.1)

Although there were no periprocedural deaths, during the follow-up period one subject died (day 280) and one subject received an LVAD (day 13).

These study results got their share of praise, and should make AccuCinch’s current CORCINCH-HF pivotal RCT trial even higher-stakes, which has the same key inclusion criteria, and would be used to support the TLVR device’s FDA Premarket Approval application. 

Takeaway

After 20 years of R&D, this data reinforces TLVR’s potential to expand and improve the treatment options available to heart failure patients. There’s still plenty more work to be done, but Ancora Heart’s catheter-based left ventricle therapy seems to be on the right track.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

Cardiology Pharmaceuticals June 16, 2025

No Need to Discontinue Abelacimab Pre-Procedure June 16, 2025

A new analysis of AZALEA-TIMI 71 suggests Anthos Therapeutics’ abelacimab is capable of reducing major bleeding in patients with AFib undergoing invasive procedures. The sub-analysis examined a total of 920 procedures across 441 patients taking either abelacimab or rivaroxaban, with approximately 1-in-3 patients undergoing an invasive procedure over a median follow-up of 2.1 years. Researchers […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!